Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Czechia / NCT07324070
Recruiting Not applicable

Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

NCT07324070 · tracked via the Priya Life Science Czechia tracker
Sponsor
Charles University, Czech Republic
Phase
Not applicable
Started
2026-01-05
Last updated
2026-01-07

Condition(s) studied

Major Depressive Disorder (MDD)Treatment Resistant Depression (TRD)

Investigational drug(s) / intervention(s)

Electroconvulsive therapyTranscranial Magnetic Stimulation

Electroconvulsive therapy: transcranial magnetic stimulation in intermitent theta burst stimulation protocol plus electroconvulsive therapy

Transcranial Magnetic Stimulation: Transcranial magnetic stimulation, intermitent theta burst stimulation or sham TMS

Study summary

The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energy

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age equal to 18 or higher * MADRS (Montgomery-Asberg Depression Scale) qual or higher than 20 * Major depressive disorder according to ICD 10 Exclusion Criteria: * Other axis 1 disorder (for example schizofrenia, addiction, etc.) * No dementia * ECT in the last 3 months * TMS in the last 3 months * Psychotic disease or symptoms * Ppregnancy or lactation * Any neurological disease (for example epilepsy, etc.) * Participation in another clinical trial within the last 30 days * somatic condition which contraindicates ECT

Primary outcome measure(s)

  • reduction of the seizure treshold of ECT — during each ECT procedure
    determine whether TMS priming using the iTBS protocol prior to ECT results in a reduction of the seizure threshold

Trial sites (1)

FacilityCityRegionStatus
General University Hospital, Psychiatry department Prague Czech Recruiting

More Charles University, Czech Republic trials in Czechia

Hyperinflammation and Hyperferritinemia in Critically Ill Patients Recruiting
Single-center Evaluation of Human Milk Quantity and Quality Over Five Years Recruiting
Fertility Limiting Diseases of Pelvic Organs and Their Influence on Receptivity of Endometrial Cavity: Prospective Clinical Trial Recruiting
Pilot Verification of the Usability of Automatic Evaluation of the Box and Block Test by a Computer Program in Occupational Therapy Practice Starting soon
LA Function After PFA in Paroxysmal AF Recruiting

Other trials for the same condition

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) Recruiting
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder Recruiting
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07324070 on ClinicalTrials.gov ↗ ← All trials in Czechia